Federal study shows link between pot use, suicide

A year and a half after Michigan’s first pot shops opened, a new study by the federal government shows a link between marijuana use and suicide in young adults.

The study by the National Institute on Drug Abuse, which analyzed data from more than 280,000 people ages 18 to 35, suggests marijuana users thought about suicide, planned suicide or attempted it more often than people who don’t use marijuana.

The findings come as marijuana usage increases across the country and as more states like Michigan — where the first marijuana stores opened in December 2019 — legalize it for recreational use. According to the National Institute on Drug Abuse, the number of adults in the United States who use cannabis jumped from 22.6 million in 2008 to 45 million in 2019. The number of daily or near-daily users increased from 3.6 million to 9.8 million during that same time.

While the researchers aren’t saying that marijuana is causing suicidal thoughts or actions, they are pointing out that people who use pot are more prone to suicidal thoughts or actions.

“While we cannot establish that cannabis use caused the increased suicidality we observed in this study, these associations warrant further research, especially given the great burden of suicide on young adults,” NIDA Director Dr. Nora Volkow, senior author of the study, said in a prepared statement. “As we better understand the relationship between cannabis use, depression and suicidality, clinicians will be able to provide better guidance and care to patients.”

Researchers studied data from four groups of people — those who do not use marijuana, those who use marijuana but don’t use it every day, those who use it daily (which, for the purposes of the study, was defined as at least 300 days a year), and those who are addicted to it.

The conclusion: Among people who did not report having depression, 3% of people who do not use marijuana reported thoughts of suicide, compared to 7% of nondaily cannabis users, 9% of daily cannabis users and 14% of those addicted to cannabis.

Among people with depression, 35% of people who did not use cannabis had suicidal thoughts, compared to 44% of those who reported nondaily cannabis use, 53% of those who used cannabis daily and 50% of those who are addicted to cannabis.

The study published online Tuesday in JAMA Network Open, the free, online journal of the American Medical Association.

https://www.freep.com/story/news/local/michigan/detroit/2021/06/22/national-institute-on-drug-abuse-links-weed-use-suicide/7746023002/

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Leave a comment

Related Posts

Weed users nearly 25% more likely to need emergency care and hospitalization

The study, published Monday in the journal BMJ Open Respiratory Research, looked at national health records data for over 30,000 Ontario, Canada, residents between the ages of 12 and 65 over a six-year period. When compared with people who did not use marijuana, cannabis users were 22% more likely to visit an emergency department or be

Cannabis use is associated with increased risk for serious adverse health events

Although no significant association was observed between cannabis use and respiratory-related ER visits or hospitalisations, the risk of an equally important morbidity outcome, all-cause ER visit or hospitalisation, was significantly greater among cannabis users than among control individuals. Therefore, cannabis use is associated with increased risk for serious adverse health events and its recreational consumption

Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores

Products containing cannabinoids such as cannabidiol (CBD) have proliferated since 2018, when the Agriculture Improvement Act removed hemp (ie, cannabis containing <0.3% Δ9-tetrahydrocannabinol [THC]) from the US controlled substances list. Topical cannabinoid products can be purchased nationwide at retail stores and over the internet, yet research on these products is scarce. The objective of this

Cannabis-Derived Oromucosal Spray Misses in MS Spasticity Trial

Topline results were announced from a phase 3 trial evaluating the efficacy and safety of nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in adults with multiple sclerosis. Nabiximols oromucosal spray is an investigational complex botanical mixture formulated from extracts of the cannabis sativa plant. The investigational treatment contains the cannabinoids delta-9-tetrahydrocannabinol (THC) and

Should the UK legalize marijuana?

After Sadiq Khan’s visit to a California cannabis farm, discussions of legalising the herb here in the UK has been brought back into the spot light. But is Mr. Khan’s glowing review of the US marijuana industry all it’s cracked up to be? The Medical Minefield speak with Michelle Leopold, whose campaigning for safer drug

Scroll to Top